UPB
NASDAQ · Biotechnology
Upstream Bio Inc
$6.31
-0.26 (-3.96%)
Financial Highlights (FY 2026)
Revenue
3.14M
Net Income
-157,817,354
Gross Margin
—
Profit Margin
-5,026.0%
Rev Growth
+33.0%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | — | — | 67.3% | 67.3% |
| Operating Margin | -5,618.8% | -5,056.9% | -2.1% | -2.1% |
| Profit Margin | -5,026.0% | -4,774.7% | -1.8% | -2.2% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 3.14M | 2.36M | 177.59M | 201.20M |
| Gross Profit | — | — | 119.60M | 135.50M |
| Operating Income | -176,443,927 | -119,362,247 | -3,738,401 | -4,294,140 |
| Net Income | -157,817,354 | -106,761,589 | -3,219,143 | -4,334,728 |
| Gross Margin | — | — | 67.3% | 67.3% |
| Operating Margin | -5,618.8% | -5,056.9% | -2.1% | -2.1% |
| Profit Margin | -5,026.0% | -4,774.7% | -1.8% | -2.2% |
| Rev Growth | +33.0% | +33.0% | -5.8% | +19.5% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 530.13M | 598.50M |
| Total Equity | — | — | 856.80M | 928.50M |
| D/E Ratio | — | — | 0.62 | 0.64 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -176,226,219 | -125,838,024 | -5,179,349 | -6,300,639 |
| Free Cash Flow | — | — | -3,332,995 | -3,816,597 |